Results 111 to 120 of about 35,907 (256)

Systemic Therapy Management Strategies for Early‐Stage Breast Cancer in Australia

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Advances in systemic therapy for early‐stage breast cancer in Australia highlight genomic‐guided decisions, subtype‐specific strategies, and emerging targeted and immunotherapies, shaping personalized and de‐escalated treatment approaches. ABSTRACT Breast cancer is the most common cancer among Australian women, with early‐stage disease (Stages I, II ...
Nicholas Zdenkowski, Rachel Dear, Sanjeev Kumar, Hilary Martin, Dhanusha Sabanathan, Stephen J. Luen, Belinda Yeo   +6 more
wiley   +1 more source

Anti-mullerian hormone in BRCA mutation carriers: a scoping review

We will comprehensively examine the literature on AMH levels in BRCA mutation carriers, exploring the potential effects of these genetic mutations on ovarian reserve and reproductive health.
Jolien Jansen
core   +1 more source

High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes

, 2017
International audiencePurpose To investigate the associations between BRCA mutation status and computed tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate CT indicators of cytoreductive outcome and survival in patients
Hebert Alberto Vargas, Mithat Gönen, Robert A. Soslow, Hedvig Hricak, Lakhman, Yulia, Soslow, Robert, Vargas, Hebert Alberto, Maura Miccò, D’Anastasi, Melvin, Micco, Maura, Arnold, Angela, Sarah A. Johnson, Sala, Evis, Krishna Juluru, Angela G. Arnold, Hricak, Hedvig, Johnson, Sarah, Melvin D’Anastasi, Debra A. Goldman, Stephanie Nougaret, Goldman, Debra, Gönen, Mithat, Kauff, Noah, Yulia Lakhman, Sosa, Ramon, Juluru, Krishna, Noah D. Kauff, Ramon E. Sosa, Evis Sala, Nougaret, Stéphanie   +29 more
core   +1 more source

APOBEC3A is a prominent cytidine deaminase in breast cancer.

PLoS Genetics, 2019
APOBEC cytidine deaminases are the second-most prominent source of mutagenesis in sequenced tumors. Previous studies have proposed that APOBEC3B (A3B) is the major source of mutagenesis in breast cancer (BRCA).
Luis M Cortez, Amber L Brown, Madeline A Dennis, Christopher D Collins, Alexander J Brown, Debra Mitchell, Tony M Mertz, Steven A Roberts   +7 more
doaj   +1 more source

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) study

BJU International, EarlyView.
Background Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53.
Heather H. Cheng, Kara N. Maxwell, Keyan Salari, Matthew R. Cooperberg, Kristin Follmer, Joanne M. Jeter, Grace Jun, Daniel J. Lee, Hiten D. Patel, Edward M. Schaeffer, Alexandra O. Sokolova, Erika M. Wolff, Daniel W. Lin   +12 more
wiley   +1 more source

More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling

, 2014
Contains fulltext : 137473.pdf (Publisher’s version ) (Open Access)Currently, most breast cancer (BC) patients receive face-to-face genetic counseling (DNA-intake) prior to BRCA-mutation testing, with generic information regarding ...
Hoogerbrugge, N., Brunner, H.G., Zelst-Stams, W.A.G. van, Prins, J.B., Spruijt, L., Mensenkamp, A.R., Sie, A.S., Ligtenberg, M.J.L.   +7 more
core   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Surgical management of breast cancer in BRCA-mutation carriers : a systematic review and meta-analysis

, 2014
This meta-analysis investigates the oncological safety of breast-conserving therapy BCT in BRCA-mutation carriers and the risk for contralateral breast cancer (CBC) compared with non-carriers, potential risk factors for ipsilateral breast recurrence (IBR)
Valachis, Antonis,, Lind, Pehr, Nearchou, Andreas D.   +2 more
core   +1 more source

Spatial Transcriptomics and Bulk RNA‐Seq Analysis Revealed Molecular Classification of Invasive Lobular Carcinoma

Cancer Science, EarlyView.
Spatial transcriptomics and bulk RNA‐seq data analysis revealed the molecular characteristics of invasive lobular carcinoma (ILC). ILC was classified into three clusters: proliferative, immunoreactive, and stromal‐rich, with different prognoses. ABSTRACT Invasive lobular carcinoma (ILC) is a special type of breast cancer.
Momoko Tokura, Jun Nakayama, Hironori Suzuki, Mieko Ochi, Miyaka Umemori, Sho Shiino, Masayuki Yoshida, Shin Takayama, Yasushi Yatabe, Yusuke Yamamoto   +9 more
wiley   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source